Edwards Lifesciences beat Wall Street first-quarter estimates, helped by robust demand for its artificial valves used in complex cardiac procedures. The earnings beat drove the stock up more than 4% in extended trading, signaling continued strength in its core heart-valve franchise.
Edwards Lifesciences beat Wall Street first-quarter estimates, helped by robust demand for its artificial valves used in complex cardiac procedures. The earnings beat drove the stock up more than 4% in extended trading, signaling continued strength in its core heart-valve franchise.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
